Grundy Scott M
Center for Human Nutrition and Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9052, USA.
Am J Cardiol. 2002 Oct 17;90(8A):11i-21i. doi: 10.1016/s0002-9149(02)02631-0.
In 2001 the National Cholesterol Education Program (NCEP) released its Adult Treatment Panel (ATP) III report. This was an evidence-based report that upgraded cholesterol management guidelines. The update was made possible by a series of large, cholesterol-lowering clinical trials. These trials demonstrated strongly the efficacy and safety of cholesterol reduction in both primary and secondary prevention of coronary heart disease (CHD). The major recommendations of the report were several. Low-density lipoprotein (LDL) cholesterol continued to be identified as the major target of cholesterol-lowering therapy. However, more emphasis was given to HDL cholesterol and triglycerides as important targets for management. The concept of CHD risk equivalents was introduced. A CHD risk equivalent represents an absolute risk for future CHD events equal to that in persons with established CHD. Diabetes was identified as a CHD risk equivalent, requiring more intensive LDL-lowering therapy. Finally, the report placed more emphasis on the metabolic syndrome as a major, multiplex risk factor requiring increased clinical attention.
2001年,美国国家胆固醇教育计划(NCEP)发布了其成人治疗小组(ATP)III报告。这是一份基于证据的报告,对胆固醇管理指南进行了更新。一系列大型降胆固醇临床试验使得此次更新成为可能。这些试验有力地证明了降低胆固醇在冠心病(CHD)一级和二级预防中的有效性和安全性。该报告的主要建议有以下几点。低密度脂蛋白(LDL)胆固醇仍然被确定为降胆固醇治疗的主要目标。然而,高密度脂蛋白胆固醇和甘油三酯作为重要的管理目标受到了更多重视。引入了冠心病风险等同物的概念。冠心病风险等同物代表未来发生冠心病事件的绝对风险,等同于已确诊冠心病患者的风险。糖尿病被确定为冠心病风险等同物,需要更强化的降低LDL治疗。最后,该报告更加重视代谢综合征,将其作为一个主要的、复杂的风险因素,需要临床给予更多关注。